✨ Onyx Summary Ocugen appointed Rita Johnson-Greene as chief financial officer, citing her leadership experience across regenerative medicine and gene therapy organizations including ARM, bluebird bio (Genetix Biotherapeutics), Spark Therapeutics, and AstraZeneca. The hire comes as Ocugen prepares to submit the first of three planned biologics license applications this year, aligning
✨ Onyx Summary Lexicon closed a public offering of 32.0 million common shares at $1.30 per share and a concurrent private placement of 22.4 million common shares plus 367,145 shares of Series B convertible preferred stock priced at $65 per share, with both transactions closing on February
✨ Onyx Summary Phathom Pharmaceuticals announced that its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 12, alongside one-on-one investor meetings during the conference. The appearance underscores the company’s ongoing investor engagement as it advances and commercializes its gastrointestinal disease
✨ Onyx Summary SpyGlass Pharma priced its initial public offering of 9.4 million shares at $16.00 per share, raising approximately $150 million in gross proceeds ahead of its Nasdaq Global Select Market debut under the ticker “SGP.” The IPO provides capital to advance the company’s late-stage, long-acting drug
✨ Onyx Summary Seer, Inc. announced it will report fourth-quarter and full-year 2025 financial results on February 26, 2026, followed by a webcasted conference call with management later that day. REDWOOD CITY, Calif., Feb. 05, 2026 – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today
✨ Onyx Summary enGene Holdings announced that CEO Ron Cooper will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11. The presentation highlights continued investor engagement as the company advances its non-viral genetic medicine platform and lead program for non-muscle invasive bladder cancer. BOSTON
✨ Onyx Summary Affinia Therapeutics said the U.S. Food and Drug Administration has accepted its IND application for AFTX-201, clearing the company to initiate a Phase 1/2 clinical trial in adults with genetically confirmed BAG3-associated dilated cardiomyopathy. The decision advances a first-in-class gene therapy program targeting a severe inherited
✨ Onyx Summary MassBio praised the enactment of the FY2026 appropriations bill, which includes a $400 million funding increase for the National Institutes of Health along with provisions advancing PBM reform and reauthorizing the Rare Pediatric Disease Priority Review Voucher program. The measure reinforces bipartisan support for federal biomedical research, which
✨ Onyx Summary Guardant Health announced its participation in several upcoming investor conferences in February and March, including events hosted by BTIG, TD Cowen, Leerink Partners, and Barclays. Management will conduct one-on-one meetings and fireside chats, with live and archived webcasts available through the company’s investor website. PALO ALTO, Calif.
✨ Onyx Summary Cellares announced a collaboration with Stanford Medicine to automate manufacturing and release testing for gene-edited hematopoietic stem cell therapies, extending its automation platforms beyond T cell therapies into a new cell modality. The effort aims to establish a standardized, scalable manufacturing foundation that can reduce variability and accelerate
✨ Onyx Summary Foghorn Therapeutics announced that management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, with CEO Adrian Gottschalk delivering a webcasted presentation and participating in one-on-one meetings. The appearance supports investor engagement as the company advances its oncology-focused pipeline built on its Gene Traffic
✨ Onyx Summary Alzheon reported new plasma biomarker analyses from its Phase 3 APOLLOE4 and Phase 2 studies showing that valiltramiprosate (ALZ-801) produced early and sustained reductions in p-tau217, correlating with cognitive, functional, and neuroimaging benefits in genetically defined Alzheimer’s patients. The data biologically validate the drug’s mechanism and
✨ Onyx Summary Kyverna Therapeutics appointed Mayo Pujols as Chief Technology Officer effective February 9, 2026, as the company prepares for a potential transition to commercial stage and a planned biologics license application for miv-cel in stiff person syndrome. The leadership change strengthens Kyverna’s manufacturing and technical operations capabilities as
SAN DIEGO, Feb. 2, 2026 – Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that its board of directors has designated the close
✨ Onyx Summary ImmunityBio announced the launch of ResQ215B, a Phase 2 outpatient study evaluating a chemotherapy- and lymphodepletion-free combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma, including Waldenström’s Macroglobulinemia. Building on prior Phase 1 data showing durable responses with CD19 CAR-NK cells plus rituximab, the study adds ANKTIVA
✨ Onyx Summary Guardant Health and collaborators reported results from the largest study to date showing that postoperative circulating tumor DNA detection with Guardant Reveal more accurately predicts recurrence and overall survival than standard staging in patients with resected stage III colon cancer. Published in the Journal of Clinical Oncology, the
